Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
At least 14 killed in explosion at weapons depot in Syria
US hits five Iranian oil tankers after attack on Navy ships
UK gives air traffic provider a week to probe outage that halted flights
Serbia's President Vucic dissolves parliament, calls snap elections
With large crowds attending, Norway lays King Harald to rest
Jordan intercepts 18 Iranian ballistic missiles
Air traffic control issue disrupts flights at major UK airports
At least 73 injured after Houthi rebels attack Saudi civilian and energy facilities
